Evidence map›Paper›PMID 29063073›Full record

ArticleChronic diseases and translational medicine2017

The association between metformin use and colorectal cancer survival among patients with diabetes mellitus: An updated meta-analysis.

Shan Tian, Hong-Bo Lei, Yu-Lan Liu, Yan Chen, Wei-Guo Dong

Abstract read
In one paragraph

Article in Chronic diseases and translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Pleiotropic Effects of Metformin on Cancer.International journal of molecular sciences · 2018
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shan TianDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Hong-Bo LeiDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Yu-Lan LiuDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Yan ChenDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.
Wei-Guo DongDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRecent studies have reported conflicting results on the correlation between metformin use and outcomes in patients with colorectal cancer (CRC). A meta-analysis was performed to evaluate the efficacy of metformin therapy on the prognosis of CRC patients with type 2 diabetes mellitus (T2DM).

methodsWe conducted a systematic search of PubMed, EMBASE, the Cochrane Library, and the Web of Science for related articles up to August 2016. Two investigators independently identified and extracted information. Pooled risk estimates [hazard ratios (

resultsOf 81 articles identified, 8 retrospective cohort studies, representing 6098 cases of CRC patients with T2DM who used metformin and 4954 cases of CRC patients with T2DM who did not use metformin, were included in this meta-analysis. There was no significant heterogeneity and quality difference between studies. Metformin users had significantly improved overall survival (OS) (

conclusionThis meta-analysis suggests that metformin use may improve survival among CRC patients with T2DM. However, prospective controlled studies are still needed to rigorously evaluate the efficacy of metformin as an anti-tumor agent.

Indexed as

Anti-tumor agentColorectal cancerMeta-analysisMetforminSurvival

Identifiers

PMID29063073
PMCPMC5643786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.